[A22-127] Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Addendum to Commission A22-81
Last updated 02.02.2023
Project no.:
A22-127
Commission:
Commission awarded on 06.12.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-targeted therapies
After addendum now hint of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-02-02 A G-BA decision was published.